INTRODUCTION {#s1}
============

Coronary artery disease (CAD), including myocardial infarction, angina pectoris and arteriosclerosis of the coronary arteries, is a leading cause of illness, disability and death worldwide, particularly in older people \[[@R1]--[@R3]\]. In China, moreover, the prevalence of CAD is increasing. The annual mortality rate due to ischemic heart disease is currently 5% among males and 3.65% among females \[[@R4]\]. Several studies have identified gender differences in CAD susceptibility that likely account for the higher mortality rate among males \[[@R5], [@R6]\].

CAD is a multifactorial disease, and both acquired and inherited components are implicated in its etiology \[[@R7]\]. While many CAD risk factors can be ameliorated through lifestyle changes, such as diet and exercise, one\'s genetic make-up and family history of the disease are not modifiable \[[@R8], [@R9]\]. Understanding the genetic factors that contribute to the development of CAD continues to be a crucial element for improving methods of effective prevention, early diagnosis and therapeutic strategies.

Among the genetic factors thought to contribute to the risk of CAD are gene single-nucleotide polymorphisms (SNPs) \[[@R10], [@R11]\]. For example, SNPs in *PHACTR1* \[[@R12]\] and *SLC22A3* \[[@R13]\] are reported to have a strong association with CAD in Lebanon and Finland, respectively. *PHACTR1* encodes phosphatase and actin regulator 1, which can mediate increased oxidation of low-density lipoproteins and is required for vascular development, but may also mediate atherosclerosis in humans \[[@R14]\]. *SLC22A3* includes 11 exons and 10 introns and encodes organic cation transporter 3 (OCT3), which plays key roles in the inactivation of biogenic amines and the removal of toxic substances \[[@R15]\]. We selected 11 *PHACTR1* and *SLC22A3* SNPs and assessed their potential to affect CAD risk.

RESULTS {#s2}
=======

A total of 376 patients with CAD and 388 healthy controls were enrolled in this case-control study. The demographic characteristics of the study population are shown in Table [1](#T1){ref-type="table"}; note the significant difference in the age distribution between the case and control groups (*p* \< 0.001).

###### Characteristics of the patients and controls

  Variables       Case            Control         Total   *p*
  --------------- --------------- --------------- ------- ----------------------------------------------
  Sex                                                     
  Male            376             388             764     
  Age, mean ±SD   59.60 ± 11.35   47.50 ± 10.64           \< 0.001[^a^](#tfn_001){ref-type="table-fn"}

*p* value was calculated using Welch\'s t tests.

Table [2](#T2){ref-type="table"} summarizes the minor allelic frequencies (MAFs) of the tested SNPs among the individuals in the case and control groups. All the SNPs in the control group were in Hardy-Weinberg equilibrium (HWE) (*p* \> 0.05). The allelic frequencies of SNPs in the control group were similar to those of the HapMap Asian population. Using the χ ^2^ test, we found that rs9381439 located in *PHACTR1* was significantly associated with decreased CAD risk (OR = 0.72; 95% CI = 0.54--0.96; *p* = 0.024).

###### Allele frequencies in patients and controls and odds ratios estimates for CAD

  SNP ID      Genes       Band     Role     Alleles A[^a^](#tfn_002){ref-type="table-fn"}/B   HWE *p*   MAF     ORs     95 % CI   *p*          
  ----------- ----------- -------- -------- ------------------------------------------------- --------- ------- ------- --------- ------------ --------------------------------------------
  rs9381439   *PHACTR1*   6p24.1   Intron   A/G                                               0.852     0.274   0.291   0.72      0.54--0.96   0.024[^\*^](#tfn_003){ref-type="table-fn"}
  rs9349379   *PHACTR1*   6p24.1   Intron   A/G                                               0.609     0.122   0.163   0.92      0.74--1.16   0.498
  rs4715166   *PHACTR1*   6p24.1   Intron   G/A                                               0.701     0.258   0.273   0.88      0.71--1.10   0.259
  rs4715167   *PHACTR1*   6p24.1   Intron   T/C                                               0.906     0.283   0.309   0.89      0.71--1.11   0.289
  rs4711939   *PHACTR1*   6p24.1   Intron   C/T                                               0.809     0.279   0.303   0.92      0.74--1.15   0.462
  rs402219    *SLC22A3*   6q25.3   Intron   G/A                                               0.902     0.430   0.424   1.02      0.85--1.29   0.842
  rs376563    *SLC22A3*   6q25.3   Intron   T/C                                               0.278     0.384   0.373   1.05      0.85--1.29   0.660
  rs2174914   *SLC22A3*   6q25.3   Intron   C/G                                               0.525     0.396   0.399   0.99      0.80--1.21   0.906
  rs2048327   *SLC22A3*   6q25.3   Intron   C/T                                               0.608     0.423   0.451   0.89      0.73--1.09   0.272
  rs2457576   *SLC22A3*   6q25.3   Intron   C/G                                               0.397     0.399   0.404   0.98      0.80--1.20   0.844
  rs1810126   *SLC22A3*   6q25.3   3′UTR    T/C                                               0.474     0.420   0.455   0.87      0.71--1.06   0.172

Abbreviations:

Minor allele; SNP, single-nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium; MAF, minor allelic frequency; OR, odds ratio; 95% CI: 95% onfidence interval.

*p* \< 0.05 indicates statistical significance.

The genotype frequencies of SNPs in the CAD and control groups showed that rs2048327 and rs1810126 were significantly associated with the risk of CAD (Table [3](#T3){ref-type="table"}). The rs2048327 "C/C" genotype was associated with a reduced risk of CAD (OR=0.60; 95 % CI: 0.37-- 0.97; *p* = 0.036), as was the rs1810126 "T/T" genotype (OR = 0.58; 95 % CI: 0.36--0.93; *p* = 0.024).

###### Association between SNP genotypes and CAD risk in the male Chinese Han population

  SNPs        Case   Control         Genotype model                                                                                                                       
  ----------- ------ --------- ----- ---------------- ----- ----- ------------------ ------ ------------ -------------------------------------------- ------ ------------ -------
  rs9381439   7      78        291   9                108   270   1.00 (reference)   0.72   0.21--2.44   0.595                                        0.69   0.47--1.01   0.057
  rs9349379   27     140       209   31               149   206   1.00               0.68   0.37--1.26   0.219                                        0.71   0.50--1.01   0.060
  rs4715166   32     148       195   36               166   183   1.00               0.70   0.38--1.28   0.249                                        0.79   0.56--1.12   0.187
  rs4715167   31     147       197   34               165   185   1.00               0.75   0.40--1.38   0.355                                        0.81   0.57--1.14   0.229
  rs4711939   30     146       200   33               158   194   1.00               0.77   0.41--1.44   0.419                                        1.18   0.73--1.91   0.489
  rs402219    74     175       127   68               190   126   1.00               1.18   0.73--1.91   0.489                                        0.86   0.59--1.24   0.421
  rs376563    51     187       138   59               171   157   1.00               1.11   0.67--1.85   0.680                                        1.43   0.99--2.04   0.051
  rs2174914   57     184       135   65               179   143   1.00               1.63   0.63--1.69   0.894                                        1.24   0.86--1.77   0.246
  rs2048327   63     192       121   81               186   119   1.00               0.60   0.37--0.97   0.036[^\*^](#tfn_004){ref-type="table-fn"}   1.01   0.69--1.46   0.979
  rs2457576   57     186       133   67               177   141   1.00               1.00   0.61--1.64   0.989                                        1.27   0.89--1.83   0.190
  rs1810126   62     192       122   84               185   119   1.00               0.58   0.36--0.93   0.024[^\*^](#tfn_004){ref-type="table-fn"}   0.98   0.67--1.41   0.905

*p* \< 0.05 indicates statistical significance;

A/B stands for minor/major alleles.

###### Logistic regression analysis of the association between SNPs and CAD risk

  SNP         Minor allele   Dominant model     Additive model                               Recessive mode                                                                     
  ----------- -------------- ------------------ -------------------------------------------- ------------------ -------------------------------------------- ------------------ --------------------------------------------
  rs9381439   A              0.69(0.48--1.00)   0.052                                        0.73(0.52--1.02)   0.064                                        0.79(0.23--2.67)   0.701
  rs9349379   A              0.71(0.51--0.99)   0.041[^\*^](#tfn_005){ref-type="table-fn"}   0.78(0.60--1.00)   0.053                                        0.78(0.43--1.42)   0.415
  rs4715166   G              0.78(0.56--1.08)   0.129                                        0.82(0.64--1.06)   0.123                                        0.78(0.44--1.39)   0.398
  rs4715167   T              0.79(0.57--1.11)   0.179                                        0.84(0.65--1.19)   0.185                                        0.82(0.45--1.49)   0.518
  rs4711939   C              0.82(0.59--1.14)   0.234                                        0.86(0.66--1.11)   0.240                                        0.84(0.46--1.54)   0.567
  rs402219    G              0.93(0.66--1.32)   0.715                                        1.05(0.83--1.32)   0.685                                        1.29(0.85--1.98)   0.235
  rs376563    T              1.35(0.96--1.89)   0.083                                        1,14(0.89--1.44)   0.296                                        0.91(0.57--1.46)   0.709
  rs2174914   C              1.18(0.84--1.66)   0.332                                        1.06(0.84--1.34)   0.638                                        0.92(0.59--1.43)   0.701
  rs2048327   C              0.87(0.61--1.24)   0.443                                        0.80(0.63--1.01)   0.062                                        0.59(0.39--0.91)   0.016\*
  rs2457576   C              1.19(0.85--1.69)   0.298                                        1.05(0.83--1.33)   0.686                                        0.87(0.56--1.36)   0.552
  rs1810126   T              0.84(0.59--1.19)   0.343                                        0.78(0.62--0.99)   0.041[^\*^](#tfn_005){ref-type="table-fn"}   0.59(0.39--0.89)   0.012[^\*^](#tfn_005){ref-type="table-fn"}

*p* \< 0.05 indicates statistical significance;

OR (95% CI) and *p*-values were adjusted for age

The minor allele of each SNP was assumed to be a risk allele compared to the wild-type allele. Three models -- additive, dominant and recessive models -- were applied to analyze the association between SNPs and CAD after adjusting for age. We found that *PHACTR1* rs9349379 was associated with reduced CAD risk in a recessive model (OR = 0.71; 95% CI = 0.51--0.99; *p* = 0.041). In addition, *SLC22A3* rs1810126 was significantly associated with decreased CAD risk in an additive model (OR = 0.78; 95% CI = 0.62--0.99; *p* = 0.041) and recessive model (OR = 0.59; 95%CI = 0.39-0.89; *p* = 0.012). *SLC22A3* rs2048327 was also associated with reduced CAD risk in a recessive model (OR = 0.59; 95% CI = 0.39--0.91; *p* = 0.016). No other polymorphisms tested were associated with CAD risk in the Chinese Han male population.

DISCUSSION {#s3}
==========

In this study we investigated the associations between the 11 SNPs in *SLC22A3* and *PHACTR1* and CAD risk in the Chinese Han male population. Among these, *PHACTR1* rs9381439 and rs9349379 and *SLC22A3* rs2048327 and rs1810126 contributed to a decreased risk of CAD in individual SNP analyses. These results suggest that *PHACTR1* and *SLC22A3* polymorphisms may be important determinants of the risk of CAD in the Chinese Han male population.

*PHACTR1* is a regulator of protein phosphatase 1 (PP1), an enzyme involved in regulating endothelial production of nitric oxide \[[@R16]\], an important modulator of cardiovascular homeostasis whose activity is elevated in in patients with end stage heart failure \[[@R17], [@R18]\]. In a genome-wide association study, *PHACTR1* rs9349379 was associated with genetic risk of CAD \[[@R19], [@R20]\]. Rs9349379 is situated within an intronic region of *PHACTR1* and is not in high linkage disequilibrium with any coding SNPs. It may therefore affect transcriptional regulation of *PHACTR1* \[[@R20]\]. In our study, we demonstrated that *PHACTR1* rs9349379 polymorphism exerts a potentially protective effect against CAD in the Chinese Han male population, which is consistent with an observation made in Lebanese cohort \[[@R12]\]. It could be supposed that the effect of *PHACTR1* rs9349379 polymorphism on CAD is not a single-factor process, but consists of complicated elements. We also showed that *PHACTR1* rs9381439 is associated with a 0.72-fold risk of CAD. To the best of our knowledge, this is the first report that this SNP is associated with CAD, though it was a relatively small-scale study, and further studies will be needed to confirm these results.

*SLC22A3* is located on 6p25.3 and is a member of the solute carrier super family. It encodes organic cation transporter 3 (OCT3) \[[@R21]\], which modulates intracellular histamine levels by mediating its release and uptake \[[@R22]\]. Histamine is a strong inflammatory mediator that can increase the permeability of vascular endothelial cells and thus increase the deposition of low-density lipoprotein (LDL) within vascular endothelial cells, thereby promoting formation of atherosclerotic plaques \[[@R23]\]. Histamine also induces expression of cytokines, chemokines and adhesion molecules and other inflammatory factors that contribute to atherosclerotic plaque formation \[[@R24]\]. Rs2048327 and rs1810126 reportedly downregulate *SLC22A3* transcription and OCT3 protein levels \[[@R25]\]. Individuals carrying these variants may therefore have altered histamine levels, which could greatly affect morbidity. It is also plausible that, by themselves, these polymorphisms have on impact on CAD risk.

Although the present study possesses sufficient power, some limitations should be considered. As we all know, CAD is very heterogeneous disease and has numerous risk factors, including poor nutrition, obesity, hypertension and diabetes. Because the sample size in our study was relatively small, and detailed information was lacking, we could not explore how genetic polymorphisms interact with those factors in CAD. The gene-gene and gene-environment interactions of *PHACTR1* and *SLC22A3* will need to be evaluated in future studies.

In sum, our study suggests that several *PHACTR1* and *SLC22A3* gene polymorphisms may exert a protective effect against the CAD in the Chinese Han male population. However, the precise function of these polymorphisms and the mechanisms by which expression of these genes affect CAD risk have yet to be determined.

MATERIALS AND METHODS {#s4}
=====================

Study participants {#s4_1}
------------------

All participants in our study were male Han Chinese. Between 2014 and 2016, we recruited a total of 376 patients diagnosed with CAD at the First Affiliated Hospital of Xi\'an Jiaotong University and 388 healthy controls. All cases were verified, and the patients were recruited without restriction regarding age or disease stage and were previously in good health. Diagnosis was based on standard coronary angiography, which revealed ≥ 70% stenosis of the main branch of a coronary artery or aortic stenosis ≥ 50%). The patients had no history of cancer, infection, nephropathy or autoimmune disease. Patients with a history of myocardial infarction, stable angina or unstable angina were also classified as CAD subjects. Excluded were subjects with chronic diseases or conditions involving the brain, liver, heart or lung, and patients with more advanced cardiovascular, metabolic or endocrine diseases. Controls were unrelated and were selected randomly. All of the controls were in good health. All were required to have a comprehensive physical examination. None had any kind of cancer, heart disease or endocrinological, metabolic or nutritional disease.

Clinical data and demographic {#s4_2}
-----------------------------

After each subject gave written informed consent, they were interviewed by a psychiatrist who collected personal information, which included region of residence, age, education status and family history of cancer. The use of samples was approved by the Human Research Committee of the First Affiliated Hospital of Xi\'an Jiaotong University for Approval of Research Involving Human Subjects.

SNP selection and genotyping {#s4_3}
----------------------------

Among the 11 SNPs selected, rs2048327 in *SLC22A3* \[[@R13]\] and rs9349379 in *PHACTR1* \[[@R26]\] are reportedly associated with CAD; other *PHACTR1* and *SLC22A3* gene SNPs were chosen at random \[[@R12], [@R13]\]. Minor allele frequencies of all SNPs were \>5% in the HapMap of the Chinese Han Beijing population. We used a GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd. Xi\'an City, China) to extract DNA from whole blood. Extracted DNA was quantified using NanoDrop2000. Genotyping was done with the Sequenom MassARRAY RS1000 system using the standard protocol recommended by the manufacturer. The multiplexed SNP MassEXTENDED assay was designed using Sequenom Mass-ARRAY Assay Design 3.0 Software \[[@R27]\]. Data were managed and analyzed using Sequenom Typer 4.0 Software. Genotype was analyzed using a Sequenom MassARRAY RS1000 system and the standard protocol recommended by the manufacturer \[[@R27], [@R28]\].

Statistical analysis {#s4_4}
--------------------

Statistical analyses were done using Microsoft Excel and SPSS 18.0 (SPSS, Chicago, IL, USA). All *p* values were two-sided, and *p* ≤ 0.05 was considered significant. Control genotype frequencies for each SNP were tested for departure from the HWE using Fisher\'s exact test. The χ^2^ test was used to compare the distribution of marker alleles and genotypes in the patients and controls \[[@R29]\]. Unconditional logistic regression analysis, adjusted for age, was used to test odds ratios (ORs) and 95% confidence intervals (CIs) \[[@R30]\]. Associations between SNPs and risk of CAD were tested in genetic models using SNP Stats software ([http://bioinfo.iconcologia.net](http://bioinfo.iconcologia.net/)). Values of OR and 95% CI were calculated as above. Finally, SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>) was used to estimate pairwise linkage disequilibrium (LD) and haplotype construction \[[@R31]\].
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